ST. LOUIS – Federal authorities will discuss COVID-19 vaccines for children ages six months to five years.
Pfizer and BioNTech filed emergency use authorization (EUA) applications for their vaccine for children between the ages of six months and four years. They reported that 1/10th of the adult dose is 80 percent effective in preventing serious illness. Moderna applied for EUA for its vaccine for children aged six months to five years. The company reported that children would receive a quarter of the adult dose. Moderna reported 51 percent efficacy in children ages six months to two years and 37 percent efficacy in children ages two to five years.
The FDA Advisory Committee will meet Tuesday, June 14 to consider the applications. click here to learn more about Pfizer and BioNTech’s vaccine for younger children. To learn more about the Moderna vaccine for smaller children, click here. Please visit the FDA Advisory Committee Meeting for more informations.
https://fox2now.com/news/fda-advisory-committee-to-discuss-vaccines-for-kids/ FDA Advisory Committee to Discuss Pediatric Vaccines